CapsoVision (NASDAQ:CV) Earns Speculative Buy Rating from Analysts at Benchmark

Key Points

• CapsoVision has received a "speculative buy" rating from Benchmark analysts, with a target price of $5.00, indicating a potential upside of 25% from its previous close.
• Other brokerages, including Roth Capital, set a price target of $6.00 and rated the stock as a "buy," while Wall Street Zen upgraded it to a "hold" rating.
• As of the report, CapsoVision shares were trading at $4.00, with a twelve-month trading range between $3.49 and $5.72.

Investment analysts at Benchmark initiated coverage on shares of CapsoVision (NASDAQ:CV - Get Free Report) in a research report issued on Monday,Benzinga reports. The firm set a "speculative buy" rating and a $5.00 price target on the stock. Benchmark's target price would suggest a potential upside of 25.00% from the stock's previous close.

Several other brokerages have also commented on CV. Roth Capital set a $6.00 price target on shares of CapsoVision and gave the stock a "buy" rating in a report on Monday. Wall Street Zen raised shares of CapsoVision to a "hold" rating in a research report on Sunday, July 13th.

CapsoVision Trading Down 6.3%

Shares of CV opened at $4.00 on Monday. CapsoVision has a twelve month low of $3.49 and a twelve month high of $5.72.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.